Table 3.
Visit | Treatment | na | Mean (SD) | Geometric Meanb | Ratio of Geometric Means (95% CI) | P Valuec |
---|---|---|---|---|---|---|
Discharge | Ticagrelor | 2263 | 2.62 (1.24) | 2.39 | 1.01 (0.99–1.02) | 0.5958 |
Clopidogrel | 2300 | 2.56 (1.15) | 2.38 | |||
Month 1 | Ticagrelor | 2103 | 2.46 (0.98) | 2.28 | 0.99 (0.97–1.01) | 0.2507 |
Clopidogrel | 2134 | 2.43 (0.91) | 2.30 | |||
Month 6 | Ticagrelor | 1513 | 2.46 (0.94) | 2.30 | 1.01 (0.99–1.04) | 0.1730 |
Clopidogrel | 1571 | 2.39 (0.91) | 2.26 |
CI indicates confidence interval.
n includes patients with osteoprotegerin samples available at both baseline and the respective visit.
The geometric means are calculated using the antilogarithms of the model‐adjusted means of the logarithm‐transformed data.
P values from an ANCOVA model with the natural logarithm of osteoprotegerin as the outcome variable and logarithm baseline osteoprotegerin and randomized treatment (ticagrelor or clopidogrel) as independent variables.